Search
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalApproved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Anemia, Pernicious
go.drugbank.com/conditions/DBCOND0004065Drugs: Ammonium molybdate · Cyanocobalamin · Ferrous cysteine glycinate · Hydroxocobalamin · Pyridoxal phosphateSynonyms: PA - Pernicious anaemiaDelorazepam
go.drugbank.com/drugs/DB01511IllicitInvestigationalIt may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. … It has been approved for marketing in Italy.
Alatrofloxacin
go.drugbank.com/drugs/DB09335ApprovedWithdrawnAlatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Chlorothiazide
go.drugbank.com/drugs/DB00880ApprovedInvestigationalVet approvedA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration.
Practolol
go.drugbank.com/drugs/DB01297ApprovedA beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Edetate calcium disodium anhydrous
go.drugbank.com/drugs/DB14598ApprovedInvestigational[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]
Mecamylamine
go.drugbank.com/drugs/DB00657ApprovedInvestigationalMecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalSince June 2016, Velpatasvir has been available as a fixed dose combination product with [DB08934], as the commercially available product Epclusa. … Notably, velpatasvir has a significantly higher barrier to resistance than the first generation NS5A inhibitors, such as [DB09027] and [DB09102], making it a highly potent and reliable alternative for